Multiplex immunoassay analysis of plasma shows differences in biomarkers related to manic or mixed mood states in bipolar disorder patients

Journal of Affective Disorders

Volumn 185, Issue , 2015, Pages 12-16

  Haenisch, Frieder ^a   Alsaif, Murtada ^a   Guest, Paul C ^a   Rahmoune, Hassan ^a   Yolken, Robert H ^c   Dickerson, Faith ^b   Bahn, Sabine ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b SHEPPARD PRATT HEALTH SYSTEM   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bipolar disorder; Inflammatory factors; Insulin; Mania; Mixed mood states; Multiplex Immunoassay

Indexed keywords

BIOLOGICAL MARKER; C PEPTIDE; CA 125 ANTIGEN; CHEMOKINE RECEPTOR CCR4; HAPTOGLOBIN; INSULIN; MATRILYSIN; PEPTIDE YY; PROGESTERONE; SORTILIN; CARRIER PROTEIN; HORMONE; SIGNAL PEPTIDE;

ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HORMONE BLOOD LEVEL; HUMAN; IMMUNOASSAY; INSULIN BLOOD LEVEL; MALE; MANIA; MIXED MOOD STATE; MOOD DISORDER; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; YOUNG MANIA RATING SCALE; AFFECT; BLOOD; INFLAMMATION; PROCEDURES; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA;

ADULT; AFFECT; BIOMARKERS; BIPOLAR DISORDER; CARRIER PROTEINS; FEMALE; HORMONES; HUMANS; IMMUNOASSAY; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE;

EID: 84934761198     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2015.05.065     Document Type: Article

References (36)

1. A. Koukopoulos, and S.N. Ghaemi The primacy of mania: a reconsideration of mood disorders Eur. Psychiatry 24 2009 125 134
2. S. Krüger, L. Trevor Young, and P. Bräunig Pharmacotherapy of bipolar mixed states Bipolar Disord. 7 2005 205 215
3. Mathers, C. D., Lopez, A. D., Murray, C. J. L. Global Burden of Disease and Risk Factors. (World Bank, 2006).
4. K.R. Merikangas Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative Arch. Gen. Psychiatry 68 2011 241 251
5. M. Burmeister, M.G. McInnis, and S. Zöllner Psychiatric genetics: progress amid controversy Nat. Rev. Genet. 9 2008 527 540
6. M.L. Phillips, and H.A. Swartz A critical appraisal of neuroimaging studies of bipolar disorder: toward a new conceptualization of underlying neural circuitry and a road map for future research Am. J. Psychiatry 171 2014 829 843
7. A.C. Andreazza Serum S100B and antioxidant enzymes in bipolar patients J. Psychiatr. Res. 41 2007 523 529
8. S.Y. Tsai, Y.Y. Yang, C.J. Kuo, C.C. Chen, and S.J. Leu Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania J. Affect. Disord. 64 2001 185 193
9. M. Spiliotaki, V. Salpeas, P. Malitas, V. Alevizos, and P. Moutsatsou Altered glucocorticoid receptor signaling cascade in lymphocytes of bipolar disorder patients Psychoneuroendocrinology 31 2006 748 760
10. A. Ortiz-Domínguez Immune variations in bipolar disorder: phasic differences Bipolar Disord. 9 2007 596 602
11. F. Haenisch Multiplex immunoassay analysis of plasma shows prominent upregulation of growth factor activity pathways linked to GSK3β signaling in bipolar patients J. Affect. Disord. 156 2014 139 143
12. E. Schwarz Identification of a biological signature for schizophrenia in serum Mol. Psychiatry 17 2012 494 502
13. J.C. Hutton Insulin secretory granule biogenesis and the proinsulin-processing endopeptidases Diabetologia 37 Suppl 2 1994 S48 S56
14. S.F. Evans Neuronal brain-derived neurotrophic factor is synthesized in excess, with levels regulated by sortilin-mediated trafficking and lysosomal degradation J. Biol. Chem. 286 2011 29556 29567
15. M.W. Jann, and S. Perspective Evidence on Pharmacologic Treatments Diagnosis and Treatment of Bipolar Disorders in Adults A Review of the 2014 489 499
16. J.I. Isojärvi Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy Ann. Neurol. 43 1998 446 451
17. P.C. Guest Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naïve schizophrenia patients Mol. Psychiatry 15 2010 118 119
18. L.D. Baker Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes Arch. Neurol. 68 2011 51 57
19. G.J. Biessels, and L.J. Kappelle Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem. Soc. Trans. 33 2005 1041 1044
20. T. Sato Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease Neurobiol. Aging 32 2011 1626 1633
21. P.C. Guest Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia Psychoneuroendocrinology 36 2011 1092 1096
22. R.K. Kalkhoff Metabolic effects of progesterone Am. J. Obstet. Gynecol. 142 1982 735 738
23. M.K. Chan Applications of blood-based protein biomarker strategies in the study of psychiatric disorders Prog. Neurobiol. 122C 2014 45 72
24. J. Tomasik, H. Rahmoune, P.C. Guest, and S. Bahn Neuroimmune biomarkers in schizophrenia Schizophr. Res. 2015 10.1016/j.schres.2014.07.025 [Epub ahead of print] PMID: 25124519.
25. M.M. Glavas Characterization of brainstem peptide YY (PYY) neurons J. Comp. Neurol. 506 2008 194 210
26. A. Piccinni Decreased plasma levels of brain-derived neurotrophic factor (BDNF) during mixed episodes of bipolar disorder J. Affect. Disord. 171 2015 167 170
27. M. Polyakova BDNF as a biomarker for successful treatment of mood disorders: a systematic and quantitative meta-analysis J. Affect. Disord. 174C 2015 432 440
28. M. Alsaif Analysis of serum and plasma identifies differences in molecular coverage, measurement variability, and candidate biomarker selection Proteomics. Clin. Appl. 6 2012 297 303
29. M. Rothermundt Inflammatory markers in major depression and melancholia J. Affect. Disord. 63 2001 93 102
30. I.E. Bauer, M.C. Pascoe, B. Wollenhaupt-Aguiar, F. Kapczinski, and J.C. Soares Inflammatory mediators of cognitive impairment in bipolar disorder J. Psychiatr. Res. 56 2014 18 27
31. T.R. Powell Putative transcriptomic biomarkers in the inflammatory cytokine pathway differentiate major depressive disorder patients from control subjects and bipolar disorder patients PLoS One 9 2014 e91076
32. S.G. Fillman, D. Sinclair, S.J. Fung, M.J. Webster, and C. Shannon Weickert Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder Transl. Psychiatry 4 2014 e365
33. N.-G. Li, Y.-P. Tang, J.-A. Duan, and Z.-H. Shi Matrix metalloproteinase inhibitors: a patent review (2011-2013) Expert Opin. Ther. Pat. 24 2014 1039 1052
34. L. Lorente Association between serum tissue inhibitor of matrix metalloproteinase-1 levels and mortality in patients with severe brain trauma injury PLoS One 9 2014 e94370
35. L.A. Buhler Matrix metalloproteinase-7 facilitates immune access to the CNS in experimental autoimmune encephalomyelitis BMC Neurosci. 10 2009 17
36. A. Schaub, and N. Neubauer [Psychotherapeutic interventions in bipolar disorders-treatment programmes, their contents and effectiveness] Fortschr. Neurol. Psychiatr. 81 Suppl 1 2013 S22 S29